Summit Corporation Outlines Clinical Development Plans for Utrophin Modulator Program for Duchenne Muscular Dystrophy
3/21/2013 12:10:04 PM
More...
|
Summit Corporation Forms Advisory Board to Support Development of Duchenne Muscular Dystrophy Program
2/13/2013 1:04:35 PM
More...
|
Summit Corporation and Children's National Medical Center Enter Utrophin Biomarker Collaboration for Duchenne Muscular Dystrophy
2/6/2013 10:31:46 AM
More...
|
Summit Corporation Release: Repeat Dosing of SMT C1100 for Treatment of Duchenne Muscular Dystrophy Meets Endpoints in Phase 1 Clinical Trial
11/7/2012 10:00:51 AM
More...
|
Summit Corporation Awarded Up to $3.6 Million From the Wellcome Trust to Support Clinical Development of Selective C. Difficile Antibiotic
10/22/2012 10:03:00 AM
More...
|
Summit Corporation Announces Positive Phase 1 Trial Results for SMT C1100 for Treatment of Duchenne Muscular Dystrophy
10/10/2012 9:24:03 AM
More...
|
Summit Corporation Receives Regulatory Approval to Commence Phase I Clinical Trial of Selective Antibiotic for the Treatment of C. Difficile Infections
9/25/2012 10:34:42 AM
More...
|
Summit Corporation Inks Breakthrough Seglin Deal With Bristol-Myers Squibb Company (BMY)
9/11/2012 7:25:56 AM
More...
|
Summit Corporation Interim Results for the Six Months Ended 31 July 2012
9/6/2012 11:57:17 AM
More...
|
Summit Corporation Notified of Grant Award From UK Technology Strategy Board
8/2/2012 10:17:42 AM
More...
|
|